Drug Response Predictor
DRP® offers clear benefits to patients by enhancing treatment success rates and reducing unnecessary treatments and to pharmaceutical companies by enabling them to deliver more effective therapies.
Our unique advantage lies in our patented cisplatin Drug Response Prediction (DRP®) technology. The DRP® is a multigene mRNA-based algorithm that predicts a patient’s likely response to platin treatment.
We firmly believe that our companion diagnostic will significantly improve cancer patient survival rates by tailoring treatment based on individual patient biology. Our DRP® technology has consistently demonstrated its ability to predict patient reactions to platin, helping to identify which patients are likely to benefit from treatment and which are not. Doctors can avoid overtreating non-responders with cisplatin, sparing them side effects and delays in potentially more effective treatments.
The Only Proven Biomarker For Cisplatin
The DRP® is a multigene mRNA-based algorithm that uses the 205 licensed genes relating to cisplatin and carboplatin sensitivity and resistance. The technology is built upon a deep systems biology analysis of all transcriptional changes in tumor cells in response to a broad range of drug types including cisplatin and carboplatin. CHOSA has refined the platin-DRP® algorithm with actual gene expression data with tumors from over 3,000 patients, proving its clinical relevance.
The DRP® uses the already available biopsy from the pathologist for its own analysis of the tumor gene expression. The DRP® prediction is based on the correlation between the tumor's gene expression profile and known response patterns to cisplatin regarding both resistance and sensitivity. A score is generated on a scale from 0 to 100, where values closer to 100 indicate a high likelihood that the patient will have a beneficial response to the drug, and values closer to 0 suggest the patient is unlikely to respond well to the treatment.
The process taken from biopsy to score takes a total of 72 hours. This score is forwarded to the oncologist who then considers this very critical information when tailoring a specific treatment plan for the patient.
Check out the video below kindly provided by Allarity Therapeutics.
Cisplatin and Immunotherapy Treatment Today
Currently, 10-15% of all cancer patients receive cisplatin or one of its analogues. Combining cisplatin (or one of its analogues) with immunotherapy has significantly improved cancer survival rates. These synergistic effects have led to a notable rise in popularity in recent years.
PD-L1 and PD-1 inhibitors are popular immunotherapy drugs recognized for their versatility across various cancer types. These treatments block the interaction between programmed cell death protein 1 (PD-1) on immune cells and PD-L1 on tumor cells, which tumors use to evade immune detection. By inhibiting this pathway, PD-(L)1 drugs re-activate the immune system, allowing it to recognize and attack cancer cells. Cisplatin enhances this effect through its ability to induce immunogenic cell death, which complements the PD-(L)1 mechanism of action, making the combination therapy even more effective. Due to this synergy, approximately 50% of PD-(L)1 treatments today are administered alongside cisplatin or carboplatin.
Our DRP technology precisely identifies patients most likely to benefit from cisplatin, including in combination with PD-(L)1 immunotherapy. By filtering out patients with low DRP scores, the response rates for combination therapies increase significantly. This not only enhances treatment effectiveness but also minimizes patient suffering by guiding those with low DRP scores toward more suitable treatment options, potentially saving crucial time in their cancer journey.
With the PD-(L)1 inhibitor market projected to grow from USD $45.8 billion in 2023 to USD $105 billion by 2028, pharmaceutical companies must differentiate themselves in this rapidly growing, yet highly competitive market.
Our DRP technology addresses this challenge by offering more personalized and effective treatments, helping companies differentiate themselves in an increasingly crowded space.
History of the DRP®
Professor Steen Knudsen, specializing in systems and molecular biology, advanced the understanding of how cancer cell lines in labs respond similarly to cancer in patients. This approach, linking drug sensitivity to tumor biology, was shared by CHOSA co-founder Peter Buhl Jensen and his collaborator Maxwell Sehested. Buhl and Sehested discovered that sensitivity and resistance patterns directly aligned with a drug’s mechanism of action.
From 2010, Knudsen and Jensen advanced DRP technology together at Medical Prognosis Institute (MPI), in Copenhagen. In 2015, they co-founded Oncology Venture, focused on applying DRP to select patients who would benefit from specific cancer treatments, while avoiding ineffective therapies.
Oncology Venture was founded by Peter Buhl Jensen, Ulla Hald Buhl, and Steen Knudsen, along with others. The company’s mission was to use the DRP technology to guide the clinical development of cancer therapies. By pairing the right drug with the right patient, DRP would enable precision medicine in oncology. Oncology Venture obtained the exclusive rights to license and commercialize DRP technology, specifically focusing on its application in clinical oncology.
The Cisplatin DRP® has a CE mark in the EU, which includes additional countries such as Norway, Lichtenstein, Turkey, Switzerland, Iceland. Additionally DRP® has received an IDE approval with the FDA. These approvals demonstrate that the Cisplatin-DRP® is thoroughly validated.
The DRP® has been clinically validated for cisplatin in breast cancer & lung cancer through retrospective clinical studies. Additionally, a prospective clinical study was performed and published in 2023 at ASCO.